A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Belotecan (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Chong Kun Dang
- 15 Sep 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 15 Sep 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 06 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Feb 2015.